VFA
ESPR

Virtus Fund Advisers’s Esperion Therapeutics ESPR Stock Holding History

Virtus Fund Advisers’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$399K Buy
+6,057
New +$326K ﹤0.01% 353
2014
Q3 		– Sell
-396
Closed -$6K – 1393
2014
Q2 		$6K Buy
+396
New +$5.72K ﹤0.01% 2816

Other funds holding ESPR

BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Virtus Fund Advisers's ESPR Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Esperion Therapeutics (ESPR) in Q4 2017: 6,057 shares worth $399K. The stake represents ﹤0.01% of the portfolio and ranks #353 among its holdings. This is a return to the name: Virtus Fund Advisers previously reported a position in ESPR as recently as Q2 2014.

Virtus Fund Advisers first reported a position in ESPR in Q2 2014 and has held it in 2 quarters since. 165 funds tracked by Wall St. Rank hold ESPR as of Q4 2017.

  • Virtus Fund Advisers held 6,057 shares of Esperion Therapeutics worth $399K as of Q4 2017.
  • Esperion Therapeutics was a new Virtus Fund Advisers position in Q4 2017.
  • Esperion Therapeutics made up ﹤0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #353 holding.
  • Virtus Fund Advisers first reported a position in Esperion Therapeutics in Q2 2014 and has held it in 2 quarters since.
  • 165 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.